MATERIAL SAFETY DATA SHEET
Product Name: Vinorelbine Tartrate Injection
1. CHEMICAL PRODUCT AND COMPANY INFORMATION
Manufacturer Name And
Hospira Australia Pty Ltd
275 North Field Drive
1 Lexia Place
Lake Forest, Illinois 60045
Mulgrave VIC 3170
Hospira, Inc., Non-Emergency
CHEMTREC: North America: 800-424-9300; International: 1-703-527-3887
Vinorelbine Tartrate Injection
butanedioate (1:2)(salt)]; Didehydrodeoxynorvincaleukoblastine tartrate.
2. HAZARD INFORMATION / CLASSIFICATION
Vinorelbine Tartrate Injection contains vinorelbine tartrate, a semi-synthetic derivative of
vinblastine, with similar general properties. Clinically, it is used to treat some types of cancers.
It is a cytotoxic agent, and in the workplace, should be considered a potential occupational
reproductive hazard, harmful to the fetus, and a potential human carcinogen. Based on clinical
use, possible target organs may include the bone marrow, gastrointestinal system, central nervous
system, peripheral nervous system, lungs, skin, gonads, and the fetus.
Information on the absorption of this product via inhalation or skin contact is not available.
There are scientific studies that suggest that personnel (e.g. nurses, pharmacists, etc.) who
prepare and administer parenteral antineoplastics (e.g. in hospitals) may be at some risk due to
potential mutagenicity, teratogenicity, and/or carcinogenicity of these materials if workplace
exposures are not properly controlled. The actual risk in the workplace is not known. Avoid
liquid aerosol generation and skin contact.
Signs and Symptoms
None known from occupational exposures. Vinorelbine tartrate is irritating to the skin, eyes, and